Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Novel Multi Epitope-based Vaccine against Monkeypox Virus: Vaccinomic approach

Version 1 : Received: 28 June 2022 / Approved: 29 June 2022 / Online: 29 June 2022 (03:43:30 CEST)

How to cite: Shantier, S.; Mustafa, M.; Abdelmoneim, A.; Fadl, H.; Elbager, S.; Makhawi, A. Novel Multi Epitope-based Vaccine against Monkeypox Virus: Vaccinomic approach. Preprints 2022, 2022060392 (doi: 10.20944/preprints202206.0392.v1). Shantier, S.; Mustafa, M.; Abdelmoneim, A.; Fadl, H.; Elbager, S.; Makhawi, A. Novel Multi Epitope-based Vaccine against Monkeypox Virus: Vaccinomic approach. Preprints 2022, 2022060392 (doi: 10.20944/preprints202206.0392.v1).

Abstract

Background: While mankind is still dealing with the COVID-19 pandemic, on May 7, 2022, a case of monkeypox virus (MPXV) has been reported to the WHO. Monkeypox is a viral zoonotic disease with characteristics comparable to those seen in smallpox cases in the past. It has been a public health threat, particularly in Africa, but recently have been circulating the world, consequently, may become a global public health threat in a very short period. Thus, the current work was planned and then constructed a multi-epitope vaccine that can evoke an immunological response against MPXV utilizing cell surface-binding protein as a target in order to develop a novel vaccine that is both safe and almost free of side effects. Results: The proposed vaccine composed of 304 amino acids and was shown to be antigenic in Vaxijen server (0. 5311) and nonallergenic in AllerTop server. The 3D structure of the designed vaccine is predicted, refined and validated by various in silico tools to assess the stability of the vaccine. Moreover, solubility of the vaccine construct was found greater than the average solubility provided by protein-Sol server indicating the solubility of the vaccine construct. Moreover, the most promising epitopes bound to MHC I and MHC II alleles were found having good binding affinities with low energies ranging between ₋7.0 - ₋8.1kcal/mol. Conclusion: We conclude from our research that the cell surface-binding protein is one of the primary proteins involved in MPXV pathogenesis. The most promising epitopes were selected using a rigorous procedure and used for vaccine design. As a result, our study will aid in the development of appropriate therapeutics and prompt the development of future vaccines against MPXV, which could serve as an important milestone in the production of an antiviral vaccine against MPXV.

Keywords

Multi Epitope; monkeypox virus (MPXV); Vaccine; Immunoinformatics; In silico; Molecular docking

Subject

LIFE SCIENCES, Biotechnology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.

We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.